Investornewsbreaks Quantum Biopharma Ltd. (NASDAQ: QNTM) Launches Retail-Ready Unbuzzd Stick Packs Across U.S. Stores

(MENAFN- Investor Brand Network) Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition Corporation has introduced a new format of its unbuzzdTM beverage supplement-“On-the-Go Powder Stick Packs”-now sold in 8-pack display boxes. Designed for convenience and portability, the new packaging supports broader retail distribution in convenience, liquor, and drug stores across the United States. The product, which accelerates alcohol metabolism and reduces hangover symptoms, is also available online in 3-pack, 8-pack, and 18-pack formats. Quantum BioPharma holds a 25.71% stake in Celly Nutrition and receives up to 7% in royalties on sales of unbuzzdTM. The company also renewed a 45-day market awareness campaign with Life Water Media beginning March 26.

To view the full press release, visit

About Quantum BioPharma Ltd.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“ Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZDTM and spun out its OTC version to a company, Celly Nutrition Corp. (“ Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition at . The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzdTM until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company's newsroom at

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: /Disclaimer

InvestorWire
Austin, Texas

512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

MENAFN26032025000224011066ID1109360561